Protea Licenses Mass Spec Technology from GWU | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protea Biosciences today announced a worldwide licensing agreement with George Washington University for mass spectrometry-based technology.

The technology, called Laser Ablation Electrospray Ionization, or LAESI, can directly identify proteins, peptides, lipids, and metabolites in biological samples, including tissue, blood, urine, and single cells, Protea said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.